Literature DB >> 1713611

Loss of transforming growth factor beta 1 receptors and its effects on the growth of EBV-transformed human B cells.

A Kumar1, T Rogers, A Maizel, S Sharma.   

Abstract

Transforming growth factor-beta (TGF-beta) is a potent negative regulator of normal human B cell growth mediated by exogenous signals, including IL-2 and low m.w. B cell growth factor 12 kDa (BCGF-12 kDa). In the present study, we investigated the regulatory linkage between viral or nonviral transformation of human B cells and the growth inhibitory effects of TGF-beta 1. A panel of EBV+ and EBV- B cell lines, derived either by in vitro EBV B cell transformation, or from cases of lymphoma was used to quantitate the negative growth effects of TGF-beta 1. The proliferative response of three EBV- B cell lines to rBCGF-12 kDa or serum was inhibited by low concentrations of TGF-beta 1 (0.2-0.5 ng/ml for 50% maximal effect), as measured by tritiated thymidine uptake and viable cellular recovery. In contrast, rBCGF-12 kDa or serum mediated proliferation of three EBV+ B cell lines was refractory to the growth inhibitory effects of TGF-beta 1. In an attempt to understand the mechanism(s) for this differential growth control in EBV+ and EBV- B cells, we studied the expression of TGF-beta 1, c-myc, and TGF-beta 1 receptors. No correlation was observed between the expression of TGF-beta 1 or c-myc gene and growth inhibition by TGF-beta 1 in the cell lines studied. Our results indicate that sensitivity or resistance to TGF-beta 1 correlated with the presence or absence (loss) of high affinity receptors for TGF-beta 1. EBV- B cell lines expressed levels of high affinity receptors similar to those found on activated normal B or T cells. In contrast, EBV+ B cell lines showed no detectable high affinity receptors. Chemical cross-linking studies with a bifunctional reagent, dissuccinimidyl suberate revealed a normal expression of type I (65-70 kDa), type II (85-90 kDa), and type III (280-300 kDa) TGF-beta 1 high affinity receptors on EBV- B cell lines. In contrast, EBV+ B cell lines did not express type I and type II receptors, whereas type III receptors were expressed but could not be inhibited by unlabeled TGF-beta 1.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1713611

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Consistent loss of functional transforming growth factor beta receptor expression in murine plasmacytomas.

Authors:  S R Amoroso; N Huang; A B Roberts; M Potter; J J Letterio
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

2.  Suppression of transforming growth factor β receptor 2 and Smad5 is associated with high levels of microRNA miR-155 in the oral mucosa during chronic simian immunodeficiency virus infection.

Authors:  Jeffy George; Mark G Lewis; Rolf Renne; Joseph J Mattapallil
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

3.  Repression of the proapoptotic cellular BIK/NBK gene by Epstein-Barr virus antagonizes transforming growth factor β1-induced B-cell apoptosis.

Authors:  Eva M Campion; Roya Hakimjavadi; Sinéad T Loughran; Susan Phelan; Sinéad M Smith; Brendan N D'Souza; Rosemary J Tierney; Andrew I Bell; Paul A Cahill; Dermot Walls
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

4.  CD44 isoforms containing exons V6 and V7 are differentially expressed on mitogenically stimulated normal and Epstein-Barr virus-transformed human B cells.

Authors:  M Kryworuckho; F Diaz-Mitoma; A Kumar
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

5.  A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells.

Authors:  J M Slingerland; L Hengst; C H Pan; D Alexander; M R Stampfer; S I Reed
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

Review 6.  Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD.

Authors:  G Tosato; J Teruya-Feldstein; J Setsuda; S E Pike; K D Jones; E S Jaffe
Journal:  Springer Semin Immunopathol       Date:  1998

7.  Loss of receptors for transforming growth factor beta in human T-cell malignancies.

Authors:  M E Kadin; M W Cavaille-Coll; R Gertz; J Massagué; S Cheifetz; D George
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

Review 8.  Transforming growth factor beta (TGF-beta) in inflammation: a cause and a cure.

Authors:  S M Wahl
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

Review 9.  The Dynamic Roles of TGF-β Signalling in EBV-Associated Cancers.

Authors:  Sharmila Velapasamy; Christopher W Dawson; Lawrence S Young; Ian C Paterson; Lee Fah Yap
Journal:  Cancers (Basel)       Date:  2018-07-27       Impact factor: 6.639

Review 10.  Epstein-Barr Virus-Encoded Products Promote Circulating Tumor Cell Generation: A Novel Mechanism of Nasopharyngeal Carcinoma Metastasis.

Authors:  Zongbei Yang; Jing Wang; Zhenlin Zhang; Faqing Tang
Journal:  Onco Targets Ther       Date:  2019-12-31       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.